Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Liquid biopsies are new technologies that allow cancer profiling of tumor fragments found in body fluids, such as peripheral blood, collected noninvasively from patients with malignancies. These assays are increasingly valuable in clinical oncology practice as prognostic biomarkers, as guides for therapy selection, for treatment monitoring, and for early detection of disease progression and relapse. However, application of these assays to rare cancers, such as pediatric and adult sarcomas, have lagged. In this article, we review the technical challenges of applying liquid biopsy technologies to sarcomas, provide an update on progress in the field, describe common pitfalls in interpreting liquid biopsy data, and discuss the intersection of sarcoma clinical care and commercial assays emerging on the horizon.

Citation

Catherine C Coombs, Tony Dickherber, Brian D Crompton. Chasing ctDNA in Patients With Sarcoma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2020 May;40:e351-e360

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 32598183

View Full Text